Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
Sherene Loi(The University of Melbourne), Christos Sotiriou(Université Libre de Bruxelles), Roberto Salgado(Institut Jules Bordet), Carsten Denkert(Philipps University of Marburg), Christine Desmedt(Breast Cancer Research Foundation), Vesa Kataja(Kuopio University Hospital), Mark J. Smyth(Peter MacCallum Cancer Centre), Stefan Michiels(Institut Gustave Roussy), Vinu José(Université Libre de Bruxelles), Nicolas Sirtaine(Université Libre de Bruxelles), Martine Piccart(Université Libre de Bruxelles), Sibylle Loibl(Goethe University Frankfurt), Heikki Joensuu(Orion Corporation (Finland)), Debora Fumagalli(Université Libre de Bruxelles), Pirkko Kellokumpu‐Lehtinen(Tampere University Hospital), Petri Bono(Helsinki University Hospital)
Cited by 1,268
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k